Exclusive: CVC and Temasek to buy $2billion generic drugs firm Alvogen

Mon Jun 22, 2015 11:21am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article | Single Page
[-] Text [+]

By Freya Berry

LONDON (Reuters) - European private equity fund CVC and Singaporean sovereign wealth fund Temasek [TEM.UL] are to buy a controlling stake in the pharmaceutical firm Alvogen, its chairman and chief executive said.

Robert Wessman, former CEO of Actavis, founded the New Jersey-based generic drugs firm in 2009.

The size of the stake the consortium ‎purchased was not disclosed, but the deal values the company at around $2 billion, a source familiar with the matter said on Monday.

The transaction is the latest sign of the hectic pace of deal-making in the healthcare sector, which has seen more than $250 billion of mergers and acquisitions so far this year, up nearly two-thirds from a year ago, according to Thomson Reuters data.

Wessman sold a stake in Alvogen to the private equity fund Pamplona in 2014. The new owners also include U.S. investment group Vatera Healthcare Partners. Wessman and Pamplona will retain a stake.

The fast-growing company currently has 350 generic products on the market and has been pushing into the Asia-Pacific region with several acquisitions, including that of South Korea's Dream Pharma last year.

"We have grown from a small base in the U.S. back in 2009 to a global player with operations in 35 countries," Wessman told Reuters. "Our growth has been 76 percent a year in the past six years, a majority being organic, but with access to network and capital from our partners you should expect to see more acquisitions."

Generic drugmakers like Alvogen are looking to get bigger to enjoy economies of scale in manufacturing and distribution, while CVC has an interest in health through previous deals, such as a 2012 investment in Chinese drugmaker Venturepharma.   Continued...

 
A woman passes a logo of state investor Temasek Holdings at their office in Singapore July 8, 2014.  REUTERS/Edgar Su